1. Home
  2. ETNB vs CXW Comparison

ETNB vs CXW Comparison

Compare ETNB & CXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • CXW
  • Stock Information
  • Founded
  • ETNB 2018
  • CXW 1983
  • Country
  • ETNB United States
  • CXW United States
  • Employees
  • ETNB 93
  • CXW N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • CXW Real Estate Investment Trusts
  • Sector
  • ETNB Health Care
  • CXW Real Estate
  • Exchange
  • ETNB Nasdaq
  • CXW Nasdaq
  • Market Cap
  • ETNB 2.2B
  • CXW 2.4B
  • IPO Year
  • ETNB 2019
  • CXW 1997
  • Fundamental
  • Price
  • ETNB $14.83
  • CXW $18.91
  • Analyst Decision
  • ETNB Buy
  • CXW Strong Buy
  • Analyst Count
  • ETNB 10
  • CXW 3
  • Target Price
  • ETNB $22.31
  • CXW $33.33
  • AVG Volume (30 Days)
  • ETNB 9.5M
  • CXW 947.9K
  • Earning Date
  • ETNB 11-06-2025
  • CXW 11-05-2025
  • Dividend Yield
  • ETNB N/A
  • CXW N/A
  • EPS Growth
  • ETNB N/A
  • CXW 57.89
  • EPS
  • ETNB N/A
  • CXW 0.95
  • Revenue
  • ETNB N/A
  • CXW $1,997,643,000.00
  • Revenue This Year
  • ETNB N/A
  • CXW $9.30
  • Revenue Next Year
  • ETNB N/A
  • CXW $11.85
  • P/E Ratio
  • ETNB N/A
  • CXW $20.01
  • Revenue Growth
  • ETNB N/A
  • CXW 1.62
  • 52 Week Low
  • ETNB $4.16
  • CXW $12.38
  • 52 Week High
  • ETNB $15.06
  • CXW $24.99
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 79.17
  • CXW 35.13
  • Support Level
  • ETNB $14.67
  • CXW $19.48
  • Resistance Level
  • ETNB $14.93
  • CXW $22.46
  • Average True Range (ATR)
  • ETNB 0.09
  • CXW 0.67
  • MACD
  • ETNB 0.06
  • CXW -0.24
  • Stochastic Oscillator
  • ETNB 41.03
  • CXW 6.55

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About CXW CoreCivic Inc.

CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.

Share on Social Networks: